A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 30, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
EGFR Mutant Advanced Non-small Cell Lung Cancer
Interventions
DRUG

JIN-A02

PO, QD

Trial Locations (10)

10400

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

NOT_YET_RECRUITING

Faculty of Medicine Ramathibodi Hospital, Mahidol University, Ratchathewi

16247

RECRUITING

The Catholic University, St. Vincent's Hospital, Suwon

28644

RECRUITING

Chungbuk National University Hospital, Cheongju-si

92868

ACTIVE_NOT_RECRUITING

Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, Orange

03722

RECRUITING

National Cancer Center, Goyang-si

03080

WITHDRAWN

Seoul National University Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

06591

NOT_YET_RECRUITING

The Catholic University, St. Mary's Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

J Ints Bio

INDUSTRY